Immune checkpoint inhibitors against cyto-toxic T-lymphocyte-associated antigen 4 (CTLA-4) (Ipilimumab) and against programmed cell death protein 1 (PD-1) (Nivolumab) are currently used in advanced melanoma. Here, PDCD1 is linked to melanoma.